A review of polycystic ovarian syndrome in adolescents

Minerva Pediatrica

Volumn 62, Issue 5, 2010, Pages 459-473

  Brewer, M ^a   Pawelczak, M ^a   Kessler, M ^a   Shah, B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; Hyperandrogenism; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; BIGUANIDE; CYPROTERONE ACETATE; DROSPIRENONE; ESTROGEN; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GONADORELIN; INSULIN; LUTEINIZING HORMONE; METFORMIN; PIOGLITAZONE; SPIRONOLACTONE; TESTOSTERONE;

ABDOMINAL DISCOMFORT; ACANTHOSIS NIGRICANS; ACNE; ALOPECIA; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG MEGADOSE; EARLY DIAGNOSIS; ENDOMETRIUM HYPERPLASIA; ENVIRONMENTAL FACTOR; FEMALE INFERTILITY; GYNECOLOGIC CANCER; HEREDITY; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LABORATORY TEST; LIFESTYLE MODIFICATION; LIVER TOXICITY; LONG TERM CARE; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; NAUSEA; NONALCOHOLIC FATTY LIVER; OBESITY; ORAL CONTRACEPTION; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; POLYURIA; PUBERTY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME;

EID: 78751632507     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome:towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992, Vol 4. pp. 377-84.
3. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction 2004;19:41-7.
4. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786-9.
5. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome:the Rotterdam Criteria are premature. J. Clin. Endocrinol. Metab. 2006;91:781-785.
6. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al. Position statement:criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-45.
7. Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril 2006;86:S6. (Pubitemid 43949267)
8. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
9. Broder-Fingert S, Shah B, Kessler M, Pawelczak M, David R. Adolescents are not appropriately evaluated for polycystic ovary syndrome in an urban population. J Clin Res Pediatr Endocrinol 2009;1:188-93.
10. Pfeifer SM, Kives S. Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin N Am 2009;36:129-52.
11. DeVore Berlan E, Emans SJ. Managing polycystic ovary syndrome in adolescent patients. J Pediatr Adolesc Gynecol 2009;22:137-40.
12. Hassan A, Gordon CM. Polycystic ovary syndrome update in adolescence. Curr Op Pediatr 2007;19:389-97. (Pubitemid 47075618)
13. Chang RJ, Coffler MS. Polycystic ovary syndrome:early detection in the adolescent. Clin Obstet Gynecol 2007;50:178-87.
14. Rosenfield RL. Clinical review:identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787-96.
15. Driscoll DA:Polycystic ovary syndrome in adolescence. Sem Reproductive Med. 2003;21:301.
16. Porter MB. Polycystic ovary syndrome:the controversy of diagnosis by ultrasound. Sem Reprod Med 2008;26:241-251.
17. Diamanti-Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol 2010;24:173-183
18. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone:an endocrine society position statement. J Clin Endocrinol Metab 2007;92:405-13. (Pubitemid 46255268)
19. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome:clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717-23.
20. Shah B, Parnell L, Milla S, Kessler M. Endometrial thickness, uterine, and ovarian ultrasonographic features in adolescents with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol 2010;23:146-56.
21. Khan U. Polycystic ovary syndrome in Adolescents. J. Pediatr Adolesc Gynecol. 2007;20:101-4.
22. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Ann Rev Med. 2001;52:401-19.
23. Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome:Mechanism and Implications for Pathogenesis. Endocrine Rev 1997;18:774-800.
24. Maciel GA, Baracat EC, Benda JA, Markham SM, Hensinger K, Change RJ et al. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5321-7.
25. Vendola K, J Zhou, Wang J, Bondy CA. Androgens promote insulin-like growth factor-1 and insulin-like growth factor receptor gene expression in the primate ovary. Hum Reprod 1999;14:2328-32. (Pubitemid 29425423)
26. Escobar-Morreale, H, San Millan, J. "Abdominal adiposity and the polycystic ovary syndrome." Trends in Endocrinol and Metab 2007;18:266-72.
27. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol 2000;163:49-52.
28. Nestler JE. Sex hormone-binding globulin:a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 1993;76:273-4.
29. Xita, N, Tsatsoulis, A. Review: Fetal programming of polycystic ovary syndrome by androgen excess:evidence from experimental, clinical and genetic association studies. J Clin Endocr Metab 2006;91:1660-6.
30. Ferriman D, Purdie AW. The inheritance of polycystic ovarian disease and possible relationship to premature balding. Clin Endocrinol 1979;1:291-9.
31. Chamberlain N, Driver E, Miesfeld R. The length and location of CAG nucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6. (Pubitemid 24260654)
32. Ibañez L, Ong KK, Mongan N, Jaaskelainen J, Marcos M, Hughes I et al. Fat distribution in non-obese girls with or without precocious pubarche:central adiposity related to insulinemia and androgenaemia from puberty to post-menarche. Clin Endocrinol 2003;58:372-9.
33. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG levels. J Clin Endocrinol Metab 2003;88:5976-80.
34. Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH et al. Association of aromatase (CYP19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837-43.
35. Ibañez L, Potau N, Francois I, Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocr Metab 1998;83:3558-62.
36. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr. Hyperfunction of hypothalamic-pituitary axis in women with polycystic ovarian disease:indirect evidence for partial gonadotroph desensitations. J Clin Endocrinol Metab 1988;66:165-72.
37. Apter D, Butzow T, Laughlin GA, Yen SS. Accelerated 24 h luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian disease. J Clin Endocrinol Metab 1994;79:99-125. (Pubitemid 24221170)
38. Veldhuis JD, Pincus M, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M. Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:72-9.
39. Diamanti-Kandarakis E, Christakou C, Palioura E, Kandaraki E, Livadas S. Does polycystic ovary syndrome start in childhood? Pediatric Endocrinology Rev 2008;5:904-11.
40. Barfield E, Liu YH, Kessler M, Pawelczak M, David R, Shah B. The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2009;22:318-23.
41. Rachmiel M, Kives S, Atenafu E, Hamilton J. Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents:a unique subgroup? Arch Pediatr Adolesc Med 2008;162:521-5.
42. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905-9.
43. Joseph-Horne R, While DM, Batty S, Franks S, Hiller SG, Urquhart M et al. Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum Reprod 2002;17:1459-63.
44. Lunn S, Mason HD, Fraser H. Structure of the corpus luteum in ovulatory polycystic ovary syndrome. Hum Reprod 2002;17:111-7.
45. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007;8:201-19.
46. Ferriman D, Gallway JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
47. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988;19:831-6.
48. Miller JA, Darley CR, Karkavitsas K, Kirby JD, Munro DD. Low sex-hormone binding globulin levels in young women with diffuse hair loss. Br J Dermatol 1982;106:331-6. (Pubitemid 12177003)
49. Kasick JM, Bergfeld WF, Steck WD, Gupta MK. Adrenal androgenic female-pattern alopecia: sex hormones and balding women. Cleve Clin Q 1983;50:111-22.
50. Schmidt JB, Lindmaier A, Trenz A, Schurz B, Spona J. Hormone studies in females with androgenic hair loss. Gynecol Obstet Invest 1991;31:235-9.
51. Legro RS. Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2002;15:1367-78.
52. Azziz R. The time has come to simplify the evaluation of the hirsute patient. Fertil Steril 2000;74:870-2.
53. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reprod Update 2003;9:505-14.
54. Shah B, Golden E, Milla S. Unilaterial ovarian enlargement in adolescents with polycystic ovary syndrome:a varient of bilateral disease. J Pediatr Endocrinol Metabol 2010;23:87-95.
55. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R, Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol (In press).
56. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C et al. Polycystic ovary syndrome:the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
57. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS et al. Differences in clinical and endocrine features between obese and nonobese subjects with polycystic ovary syndrome:an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32:213-20.
58. Goldzieher JW, Axelrod LR. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril 1963;14:631-3.
59. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between non-obese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682-88.
60. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome:a position statement of the androgen excess and polycystic ovary syndrome society. Fertil Steril 2009;92:1966-82.
61. Dunaif A, Segal KR, Futterweith W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
62. The DECODE study group. Glucose tolerance and mortality:comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999;354:617-21.
63. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999;22:920-4.
64. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-74.
65. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clinical Endocrinol Metab 2006;91:492.
66. Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A et al. Prevalence of syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:4780-6.
67. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and non-alcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1741-7.
68. Stefan N, Schick F, Haring HU. Sex hormone-binding globulin and risk of type 2 diabetes. N Engl J Med 2009;361:2675-6.
69. Cook S. The metabolic syndrome:antecedent of adult cardiovascular disease in pediatrics. J Pediatrics 2004;145:427-30. (Pubitemid 39345972)
70. Karadeniz M, Erdogan M, Tamsel S, Zengi A, Alper GE, Caglayan O et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulina resistances. Exp Clin Endocrinol Diabetes 2008;116:231-5. (Pubitemid 351600585)
71. Lakhani K, Hardiman P, Seifaliam AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004;175:353-9. (Pubitemid 38942916)
72. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;987:325-31.
73. Smyczek-Gargya B, Geppert M. Endometrial cancer associated with polycystic ovaries in young women. Path Res Pract 1992;188:948-50.
74. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers:is there a link? Gynecol Endocrinol 2005;20:200-8.
75. Trent ME, Rich M, Austin B, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome:implications for quality of life. J Pediatr Adolesc Gynecol 2003;16:33-7.
76. Harris-Glocker M, Davidson K, Kochman L, Guzick D, Hoeger K. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril 2010;93:1016-8.
77. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women. Postgrad Med J 1993;69:186-9.
78. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome:a comprehensive investigation. Fertil Steril 2010;93:2421-3.
79. Spear BA, Barlow SE, Ervin C, Ludwig DS, Saelens BE, Schetzina KE et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics 2007;120(Suppl 4):S254-S288.
80. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36:105-11.
81. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-12.
82. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistendy increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586-93.
83. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-5.
84. Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome:role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4.
85. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries:parallel improvements in anthropomorphic indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;18:1928-32.
86. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88.812-9.
87. Hoeger KM. Role of lifestyle modification in the management of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol MeUb 2006;20:293-310. (Pubitemid 43842932)
88. Wabitsch M, Hauner H, Heinze E, Böckmann A, Benz R, Mayer H et al. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab. 1995;80:3469-75.
89. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
90. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance:amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-9. (Pubitemid 34615238)
91. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002;16:217-24.
92. Ibañez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000;85:3526-30.
93. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160-9.
94. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-8.
95. Soares GM, Vieira CS, de Paula Martins W, Dos Reis RM, de Sa MF, Ferriani RA. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract 2009;63:160-9.
96. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinology & Metabol 2008;93:4299-306.
97. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006;85:420-7.
98. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52:527-94.
99. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Burgari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol1999;141:361-7.
100. Gotland IM, Elstein ME. Results of an open one-year study with diane-35 women with polycystic ovarian syndrome. Ann NY Acad Sci 1993;687:263-71.
101. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F et al. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism:a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94. (Pubitemid 32268796)
102. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006;142:298-302.
103. Balfour Ja, McClellan K. Topical eflornithine. Am J Clin Dermatol 2001;2:197-201.
104. DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female.Ttreatment with 2% topical minoxidil solution. Arch Dermatol 1994;130:303-7.
105. Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alpecia in women. Int J Dermatol 1993;32:758-62.
106. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004;50:541-53.
107. Price VH. Androgenetic alopecia in adolescents. Cutis 2003;71:115-21.
108. Georgala S, Befbn A, Maniatopoulou E, Georgala C. Topical use of minoxidil in children and systemic side effects. Dermatology 2007;214:101-2.